AbstractA survey conducted by the Special Interest Group on Adverse Reactions (SIGAR) identified an interest in developing a formal educational programme on pharmacovigilance. The majority of potential delegates had between 1 and 5 years of experience in pharmacovigilance and held higher qualifications. They were prepared to provide up to 6 hours of self‐study per week but only a minority would sponsor themselves.Managers envisaged providing at least one candidate for up to three modules per annum. Preferred modules included regulatory requirements and guidelines, spontaneous reporting, methodologies and company systems. As a result of this favourable response an academic partner has been appointed in the United Kingdom and the course will commence in 199
展开▼